Print

Symphogen A/S Presents New pan-HER data at Annual American Association for Cancer Research Meeting  
4/10/2013 6:31:43 AM

Symphogen today at the Annual Meeting of the American Association for Cancer Research in Washington DC, presented new preclinical data suggesting that a mixture of antibodies, known as pan-HER, that simultaneously inhibits EGFR, HER2 and HER3, is superior to existing targeted therapies in dealing with both primary and acquired resistance due to HER family dependency.
//-->